Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 10/20 | 0.59 |
| ▸ | RARB | P10826 | 10/20 | 0.59 |
| ▸ | RARG | P13631 | 10/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064853 | 0.89 | RARA (0.46) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2065252 | 0.87 | MCHR1 (0.47) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2064249 | 0.86 | S1PR1 (0.47) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2064868 | 0.85 | MCHR1 (0.49) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL3721244 | 0.84 | S1PR1 (0.43) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2064319 | 0.84 | S1PR1 (0.48) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2063945 | 0.84 | RARA (0.40) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2065052 | 0.84 | RARA (0.40) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2065005 | 0.84 | HDAC4 (0.52) | RARARARBRARGS1PR1S1PR3 | |
| SCHEMBL2064962 | 0.83 | RARA (0.41) | RARARARBRARGS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222667-B1 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-8148410-B2 | Thiophene derivatives as agonists of S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-04-03 | — | — | US | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | RARA 4268/4885RARB 3715/4885RARG 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.